DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1751)

Migraine | Emerging Therapies | Ajovy and Emgality: Migraine Prevention (Wave 1) US

Migraine | Emerging Therapies | Ajovy and Emgality: Migraine Prevention (Wave 1) US

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming December 2018

Market Outlook

The migraine prophylaxis market stands poised for disruption following the launch of three anti-CGRP monoclonal antibodies (MAbs) in the United States in 2018, with a fourth to launch in 2020. Amgen/Novartis’s Aimovig (erenumab) was the first to launch in May, giving it an approximately four-month head-start over Teva’s Ajovy and Eli Lilly’s Emgality. This U.S. launch-tracking series—DRG’s companion to our three-wave Aimovig series—will assess Ajovy and Emgality’s uptake and performance through Year 1. Additionally, we will examine how Ajovy, Emgality, and Aimovig compare on a number of attributes and assess how physician adoption, opinion, and expectations shift as they gain more experience with each of these novel therapies.

Questions Answered

  • How quickly do U.S. neurologists adopt Ajovy and Emgality, and what percentage of their migraine patients do they consider candidates for each?
  • When and for which migraine patients are neurologists prescribing Ajovy and Emgality, what are the reasons for prescribing, and how satisfied are they with Ajovy and Emgality, as well as Aimovig? Which anti-CGRP MAb performs the best on clinical and nonclinical attributes?
  • How do adopters and nonadopters of Ajovy and Emgality compare across key metrics? What attributes differentiate Ajovy and Emgality from each other and Aimovig in the minds of prescribers?
  • What promotional messages do neurologists recall in support of the Ajovy and Emgality launch? What, if any, messages have been communicated by marketers to differentiate each drug from its competitors?

Product Description

Emerging Therapies is a three-wave series based on primary research data collected at one, six, and twelve months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as the impact on current therapies and anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Markets covered: United States

Primary research: Survey of 75 U.S. neurologists for each wave

Key metrics included:

  • Unaided and Aided Awareness of Ajovy and Emgality
  • Familiarity with and Impressions of Ajovy and Emgality
  • Prescriber and Nonprescriber Profiles
  • Willingness to Prescribe Ajovy and Emgality
  • Performance of Ajovy and Emgality on Key Attributes and in Comparison with Each Other and Aimovig
  • Sales Representative Frequency, Reach, and Satisfaction
  • Benchmarking Against Aimovig

Table of contents

  • Ajovy and Emgality: Migraine Prevention (Wave 1) US
    • Coming Soon

Already a Client? Log in to access this report.

  • Pub Date: November 2018
  • Author(s): Angela Sparrow, PhD
  • Angela Sparrow provides expert insight and authors primary market research and forecasting content as a member of the Central Nervous System and Ophthalmology Team. During her time with the company, Angela has extensively covered migraine, contributing to numerous reports while staying up-to-date on the latest trends and news. Additionally, she provides detailed responses to client inquiries and has authored content focused on psychiatric indications, including opioid addiction and depression, as well as neuropathic pain. Dr. Sparrow holds a in behavioral neuroscience from the University of North Carolina at Chapel Hill and a Bachelor’s degree from Northeastern University. Before joining DRG, she was a postdoctoral fellow at McLean Hospital, Harvard Medical School, studying the role of kappa opioid receptors in addiction and withdrawal-induced depression.

Purchase Report

Recent reports:
You may also be interested in: